XBiotech Inc.

XBiotech Inc. が 2015年7月29日 に発表した内容

2023年12月31日 に終了した四半期、前年同期との比較。

これは単独四半期の数字であって通年ではありません——このサイトの他の場所の数字は 12 か月を対象としており、はるかに大きくなります。季節性のある事業は両者の間で大きく振れます：ServiceNow は 12 月期に 20 億ドルのフリーキャッシュフローを稼ぎ、6 月期には 5 億ドルです。

比較対象はアナリスト予想ではなく前年同期です。「上振れ」「下振れ」と言うにはコンセンサス予想が必要ですが、それは当方が保有しないライセンスデータであり——間違えるくらいなら載せないほうがましです。

決算説明会

XBiotech Inc. の決算説明会の書き起こしはありません。

XBiotech Inc. の事業内容

XBiotech is pioneering a new era in the discovery and development of targeted antibodies based on its True Human TM technology. The Company's mission is to rethink the way antibody medicines are discovered and commercialized by advancing its robust pipeline of truly natural human antibodies for treating serious diseases such as cancer, inflammatory conditions and infectious diseases. XBiotech's lead product, Xilonix™, is a potential breakthrough antibody therapy that is currently the subject of two pivotal clinical studies for treating patients with advanced colorectal cancer. Xilonix specifically targets and neutralizes interleukin-1 alpha (IL-1a), a molecule known to promote angiogenesis, growth and spread of tumors, as well as mediate symptoms such as metabolic dysregulation, fatigue and anxiety associated with advanced cancer. XBiotech believes that its broad pipeline of True Human antibodies will be able to potentially deliver unmatched safety and efficacy because they are cloned directly from individual donors who possess natural immunity against certain targeted diseases. As such, XBiotech expects that True Human antibodies will retain their natural physiology and tolerance profile, having passed the rigors of immune selection in the body.

発表資料の末尾に記載された、企業自身による説明です。